FY2026 EPS Estimates for AbbVie Raised by Leerink Partnrs

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Leerink Partnrs lifted their FY2026 earnings per share (EPS) estimates for shares of AbbVie in a report released on Sunday, July 6th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $14.03 for the year, up from their previous estimate of $14.01. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2028 earnings at $17.69 EPS and FY2029 earnings at $19.07 EPS.

ABBV has been the topic of several other reports. Citigroup boosted their target price on AbbVie to $205.00 and gave the stock a “hold” rating in a report on Wednesday, June 11th. Evercore ISI boosted their target price on AbbVie from $204.00 to $205.00 and gave the stock an “outperform” rating in a report on Monday, April 28th. The Goldman Sachs Group restated a “neutral” rating and set a $194.00 target price on shares of AbbVie in a report on Tuesday, April 8th. Erste Group Bank upgraded AbbVie to a “strong-buy” rating in a report on Monday, March 17th. Finally, Morgan Stanley lifted their price target on shares of AbbVie from $241.00 to $250.00 and gave the company an “overweight” rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $211.29.

AbbVie Trading Up 0.5%

Shares of AbbVie stock opened at $190.74 on Tuesday. The stock has a market cap of $336.92 billion, a P/E ratio of 81.17, a P/E/G ratio of 1.28 and a beta of 0.48. The stock’s 50 day simple moving average is $187.10 and its 200-day simple moving average is $188.78. AbbVie has a 1-year low of $163.81 and a 1-year high of $218.66. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The business had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same period in the prior year, the company posted $2.31 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date is Tuesday, July 15th. AbbVie’s payout ratio is 279.15%.

Hedge Funds Weigh In On AbbVie

Several institutional investors have recently modified their holdings of ABBV. Norges Bank acquired a new position in shares of AbbVie in the fourth quarter worth $4,459,385,000. GAMMA Investing LLC grew its stake in shares of AbbVie by 25,841.6% in the first quarter. GAMMA Investing LLC now owns 10,234,737 shares of the company’s stock worth $2,144,382,000 after acquiring an additional 10,195,284 shares in the last quarter. Nuveen LLC acquired a new position in shares of AbbVie in the first quarter worth $1,819,154,000. FMR LLC grew its stake in shares of AbbVie by 32.8% in the fourth quarter. FMR LLC now owns 18,097,375 shares of the company’s stock worth $3,215,903,000 after acquiring an additional 4,466,971 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of AbbVie by 31.6% in the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock worth $3,068,820,000 after acquiring an additional 3,519,187 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.